CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2019--
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company
pioneering messenger RNA (mRNA) therapeutics and vaccines to create a
new generation of transformative medicines for patients, announced today
that CEO Stéphane Bancel will present an update on the Company and its
pipeline of mRNA development programs at this year’s 37th annual
J.P. Morgan Healthcare Conference.
Mr. Bancel’s presentation will take place on Tuesday, January 8, 2019 at
10:30 a.m. PT in the Colonial Room at The Westin St. Francis Hotel in
San Francisco. The presentation will be followed by a question and
answer session. A live webcast of both the presentation and question and
answer session can be accessed on the investors section of Moderna’s
website at investors.modernatx.com.
A replay of the webcast also will be archived on Moderna’s website for
up to 30 days following the presentation.
Moderna is advancing messenger RNA (mRNA) science to create a new class
of transformative medicines for patients. mRNA medicines are designed to
direct the body’s cells to produce intracellular, membrane or secreted
proteins that can have a therapeutic or preventive benefit and have the
potential to address a broad spectrum of diseases. Moderna’s platform
builds on continuous advances in basic and applied mRNA science,
delivery technology and manufacturing, providing Moderna the capability
to pursue in parallel a robust pipeline of new development candidates.
Moderna is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases and cardiovascular diseases,
independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has strategic
alliances for development programs with AstraZeneca and Merck & Co., as
well as the Defense Advanced Research Projects Agency (DARPA), an agency
of the U.S. Department of Defense; the Biomedical Advanced Research and
Development Authority (BARDA), a division of the Office of the Assistant
Secretary for Preparedness and Response (ASPR) within the U.S.
Department of Health and Human Services (HHS). Moderna has been ranked
in the top ten of Science’s list of top biopharma industry
employers for the past four years. To learn more, visit www.modernatx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005536/en/
Source: Moderna, Inc.
Head of Corporate Communications
Chief Financial Officer